- Home
- OLP vs ANAB Comparison
OLP vs ANAB Comparison
Compare OLP & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- ANAB
- Stock Information
- Founded
- OLP 1982
- ANAB 2005
- Country
- OLP United States
- ANAB United States
- Employees
- OLP N/A
- ANAB N/A
- Industry
- OLP Real Estate Investment Trusts
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- ANAB Health Care
- Exchange
- OLP Nasdaq
- ANAB Nasdaq
- Market Cap
- OLP 569.9M
- ANAB 621.1M
- IPO Year
- OLP N/A
- ANAB 2017
- Fundamental
- Price
- OLP $23.17
- ANAB $26.94
- Analyst Decision
- OLP Strong Buy
- ANAB Buy
- Analyst Count
- OLP 1
- ANAB 10
- Target Price
- OLP $28.00
- ANAB $49.00
- AVG Volume (30 Days)
- OLP 71.6K
- ANAB 526.3K
- Earning Date
- OLP 08-05-2025
- ANAB 08-08-2025
- Dividend Yield
- OLP 7.77%
- ANAB N/A
- EPS Growth
- OLP N/A
- ANAB N/A
- EPS
- OLP 1.35
- ANAB N/A
- Revenue
- OLP $92,152,000.00
- ANAB $111,872,000.00
- Revenue This Year
- OLP $11.87
- ANAB N/A
- Revenue Next Year
- OLP $4.72
- ANAB $24.39
- P/E Ratio
- OLP $17.20
- ANAB N/A
- Revenue Growth
- OLP 3.31
- ANAB 387.20
- 52 Week Low
- OLP $22.32
- ANAB $12.21
- 52 Week High
- OLP $30.45
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- OLP 37.17
- ANAB 66.30
- Support Level
- OLP $22.98
- ANAB $25.48
- Resistance Level
- OLP $23.65
- ANAB $28.50
- Average True Range (ATR)
- OLP 0.42
- ANAB 1.26
- MACD
- OLP -0.05
- ANAB 0.02
- Stochastic Oscillator
- OLP 16.78
- ANAB 70.23
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).